ArticleThe New England journal of medicine2024
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma.
Abstract readLetter
In one paragraph
Article in The New England journal of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of esophageal cancer (update 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Guideline
- Gastric Carcinoma: Diagnosis, Staging, and Treatment.Deutsches Arzteblatt international · 2026Guideline
- Expression of Claudin-18.2 in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Trial
- First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.Nature medicine · 2026Trial
- Randomized phase II trial of zolbetuximab as second-line treatment in patients with claudin 18.2-positive advanced gastric/GEJ cancer with previous zolbetuximab exposure: ZELDA.ESMO gastrointestinal oncology · 2026Article
- Claudin-18.2: Molecular mechanisms to clinical translation in solid tumors (Review).Oncology letters · 2026Review
- Article
- Extracellular vesicle proteins monitor and interfere with CLDN18.2-targeted CAR-T cell and antibody therapies against gastrointestinal cancers.Nature communications · 2026Article
- Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial.ESMO gastrointestinal oncology · 2026Article
- Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer.ESMO gastrointestinal oncology · 2026Article
- Zolbetuximab-Associated Gastritis in a Patient With Metastatic Gastric Adenocarcinoma.ACG case reports journal · 2026Article
- Pathological Complete Response Following mFOLFOX6 Plus Zolbetuximab and Conversion Surgery in Initially Unresectable CLDN18.2-Positive Advanced Gastric Cancer: A Case Report.Journal of gastrointestinal cancer · 2026Article
- Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis.Cancer chemotherapy and pharmacology · 2026Article
- PIWIL1 activates the R2TP-TELO2-mTORC1 axis independently of piRNA to promote TOP mRNA translation in gastric cancer.Oncogene · 2026Article
- Conversion surgery after response to zolbetuximab-based chemotherapy in Claudin 18.2-positive gastric cancer: a case report.Journal of surgical case reports · 2026Article
- Surgical Intervention After Zolbetuximab-Based Chemotherapy for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A Case Series.Journal of gastrointestinal cancer · 2026Article
- Claudin proteins as emerging therapeutic targets for solid tumours.Nature reviews. Cancer · 2026Review
- Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies.Journal of hematology & oncology · 2026Review
- Complex aberrant expression of planar nuclear polarity factors in intraductal papillary mucinous neoplasm of the pancreas.Virchows Archiv : an international journal of pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Kohei ShitaraNational Cancer Center Hospital East, Kashiwa, Japan.ORCID 0000-0001-5196-3630
Manish A ShahWeill Cornell Medical College, New York, NY.ORCID 0000-0002-6913-9655
Florian LordickUniversity of Leipzig Medical Center, Leipzig, Germany.
Eric Van CutsemUniversity Hospitals Gasthuisberg, Leuven, Belgium.
David H IlsonMemorial Sloan Kettering Cancer Center, New York, NY.
Samuel J KlempnerMassachusetts General Cancer Center, Boston, MA.
Yoon-Koo KangAsan Medical Center, Seoul, South Korea.
Sara LonardiIstituto Oncologico Veneto IRCCS, Padua, Italy.
Yi-Ping HungTaipei Veterans General Hospital, Taipei, Taiwan.
Kensei YamaguchiCancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Peter EnzingerDana-Farber Cancer Institute, Boston, MA.
Tomoko NakajimaAstellas Pharma Global Development, Northbrook, IL.
Maria MatsangouAstellas Pharma Global Development, Northbrook, IL.
Ying CaoAstellas Pharma Global Development, Northbrook, IL.
Ran LiAstellas Pharma Global Development, Northbrook, IL.
Diarmuid MoranAstellas Pharma Global Development, Northbrook, IL.
Rupesh PophaleAstellas Pharma Global Development, Northbrook, IL.
Mok OhAstellas Pharma Global Development, Northbrook, IL.
Radhika RanganathAstellas Pharma Global Development, Northbrook, IL.
Jaffer A AjaniUniversity of Texas M.D. Anderson Cancer Center, Houston, TX.ORCID 0000-0001-9946-0629
Rui-Hua XuSun Yat-sen University Cancer Center, Guangzhou, China xurh@sysucc.org.cn.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdenocarcinomaEsophageal NeoplasmsEsophagogastric JunctionStomach NeoplasmsAdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase III as TopicFemaleHumansMaleMiddle AgedMulticenter Studies as TopicNauseaAntibodies, Monoclonalzolbetuximab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.